Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057876 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 74
- Enrollment target
NCT00057876 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 74 participants.
The verdict
NCT00057876, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 74 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether gemcitabine is more effective with or without radiation therapy in treating pancreatic cancer. PURPOSE: Randomized phase III trial to study the effectiveness of gemcitabine with or without radiation therapy in treating patients who have locally advanced, unresectable pancreatic cancer.
Interventions
- DRUG Gemcitabine
- RADIATION radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2003-08-29 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057876
The ClinicalTrials.gov registry entry for NCT00057876 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00057876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057876 about?
NCT00057876 is a clinical study titled "Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether gemcitabine is more effective with or without radiation therapy in treating pancrea...
What is the current status of trial NCT00057876?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 74 participants. The study started on 2003-08-29. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00057876?
The interventions under investigation include: Gemcitabine (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00057876?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.